<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01441635</url>
  </required_header>
  <id_info>
    <org_study_id>M12-663</org_study_id>
    <nct_id>NCT01441635</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids</brief_title>
  <official_title>Phase 2a Proof Of Concept Study to Evaluate the Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this proof-of-concept study is to assess the safety and effectiveness of
      elagolix versus placebo to reduce uterine bleeding associated with uterine fibroids, and to
      reduce fibroid volume and uterine volume in premenopausal women 20 to 49 years of age with
      heavy uterine bleeding.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 8, 2011</start_date>
  <completion_date type="Actual">May 17, 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline to the Last 28 Days of Treatment in Menstrual Blood Loss (MBL)</measure>
    <time_frame>Baseline (last menstrual cycle during the screening period) and the last 28 days of treatment (approximately days 61 to 90)</time_frame>
    <description>The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.
Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to the Last 28 Days of Treatment in Menstrual Blood Loss (MBL)</measure>
    <time_frame>Baseline (last menstrual cycle during the screening period) and the last 28 days of treatment (approximately days 61 to 90)</time_frame>
    <description>The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.
Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With MBL &lt; 80 mL and With a ≥ 50% Reduction From Baseline in MBL During the Last 28 Days of Treatment</measure>
    <time_frame>Baseline (last menstrual cycle during the screening period) and the last 28 days of treatment (approximately days 61 to 90)</time_frame>
    <description>The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.
Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With MBL &lt; 80 mL During the Last 28 Days of Treatment</measure>
    <time_frame>The last 28 days of treatment (approximately days 61 to 90)</time_frame>
    <description>The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.
Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a ≥ 50% Reduction From Baseline in MBL During the Last 28 Days of Treatment</measure>
    <time_frame>Baseline (last menstrual cycle during the screening period) and the last 28 days of treatment (approximately days 61 to 90)</time_frame>
    <description>The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.
Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With No Change, Decrease From Baseline, or Increase From Baseline in Hemoglobin at Month 3</measure>
    <time_frame>Baseline and Month 3</time_frame>
    <description>The percentage of subjects with changes in hemoglobin concentration from Baseline to Month 3 in each of the following categories:
No change from baseline in hemoglobin
Decrease from baseline in hemoglobin ≥ -0.5 g/dL
Decrease from baseline in hemoglobin ≥ -1.0 g/dL
Increase from baseline in hemoglobin ≥ 0.5 g/dL
Increase from baseline in hemoglobin ≥ 1.0 g/dL
The above categories are not all mutually exclusive or exhaustive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin Concentration From Baseline to Month 3</measure>
    <time_frame>Baseline and Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 3 in Uterine Bleeding Score</measure>
    <time_frame>Baseline (average bleeding score over the 30 days prior to first dose) and month 3 (average bleeding score over days 61 to 90)</time_frame>
    <description>Participants recorded the previous days' presence and severity of bleeding every morning in an electronic diary (eDiary) according to the Mansfield-Voda-Jorgenson Menstrual Bleeding Scale:
1 (Spotting): A drop or 2 of blood, not even requiring sanitary protection.
2 (Very light): Needing to change the least absorbent tampon or pad 1 to 2 times per day.
3 (Light): Needing to change a low or regular absorbency tampon or pad 2 or 3 times per day.
4 (Moderate): Needing to change a regular absorbency tampon or pad every 3 to 4 hours.
5 (Heavy): Needing to change a high absorbency tampon or pad every 3 to 4 hours.
6 (Very heavy/gushing): Very heavy bleeding, protection hardly works at all; needing to change the highest absorbency tampon or pad every hour or 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 3 in Percentage of Days With Any Uterine Bleeding</measure>
    <time_frame>Baseline (average bleeding score over the 30 days prior to first dose) and month 3 (average bleeding score over days 61 to 90)</time_frame>
    <description>Participants recorded the previous days' presence and severity of bleeding every morning in an electronic diary (eDiary) according to the Mansfield-Voda-Jorgenson Menstrual Bleeding Scale:
1 (Spotting): A drop or 2 of blood, not even requiring sanitary protection.
2 (Very light): Needing to change the least absorbent tampon or pad 1 to 2 times per day.
3 (Light): Needing to change a low or regular absorbency tampon or pad 2 or 3 times per day.
4 (Moderate): Needing to change a regular absorbency tampon or pad every 3 to 4 hours.
5 (Heavy): Needing to change a high absorbency tampon or pad every 3 to 4 hours.
6 (Very heavy/gushing): Very heavy bleeding, protection hardly works at all; needing to change the highest absorbency tampon or pad every hour or 2.
A day with any uterine bleeding is defined as a days with a bleeding score ≥ 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 3 in Percentage of Days With Moderate to Very Heavy Bleeding</measure>
    <time_frame>Baseline (average bleeding score over the 30 days prior to first dose) and month 3 (average bleeding score over days 61 to 90)</time_frame>
    <description>Participants recorded the previous days' presence and severity of bleeding every morning in an electronic diary (eDiary) according to the Mansfield-Voda-Jorgenson Menstrual Bleeding Scale:
1 (Spotting): A drop or 2 of blood, not even requiring sanitary protection.
2 (Very light): Needing to change the least absorbent tampon or pad 1 to 2 times per day.
3 (Light): Needing to change a low or regular absorbency tampon or pad 2 or 3 times per day.
4 (Moderate): Needing to change a regular absorbency tampon or pad every 3 to 4 hours.
5 (Heavy): Needing to change a high absorbency tampon or pad every 3 to 4 hours.
6 (Very heavy/gushing): Very heavy bleeding, protection hardly works at all; needing to change the highest absorbency tampon or pad every hour or 2.
A day with moderate to very heavy bleeding is defined as a days with a bleeding score ≥ 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Any Uterine Bleeding or Moderate to Very Heavy Uterine Bleeding at Month 3</measure>
    <time_frame>Month 3 (average bleeding score over days 61 to 90)</time_frame>
    <description>Participants recorded the previous days' presence and severity of bleeding every morning in an eDiary according to the Mansfield-Voda-Jorgenson Menstrual Bleeding Scale:
1 (Spotting): A drop or 2 of blood, not even requiring sanitary protection.
2 (Very light): Needing to change the least absorbent tampon or pad 1 to 2 times per day.
3 (Light): Needing to change a low or regular absorbency tampon or pad 2 or 3 times per day.
4 (Moderate): Needing to change a regular absorbency tampon or pad every 3 to 4 hours.
5 (Heavy): Needing to change a high absorbency tampon or pad every 3 to 4 hours.
6 (Very heavy/gushing): Very heavy bleeding, protection hardly works at all; needing to change the highest absorbency tampon or pad every hour or 2.
Any bleeding is defined as a score ≥ 1 and moderate to very heavy bleeding is defined as a score ≥ 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Suppression of Bleeding (Spotting Allowed) or Amenorrhea During the Last 56 Days of Treatment</measure>
    <time_frame>The last 56 days of treatment (approximately days 33 to 90)</time_frame>
    <description>Suppression of bleeding is defined as no record of bleeding (spotting allowed) in the e-diary and no record of bleeding Indicated in the alkaline hematin data during the last 56 days of treatment.
Amenorrhea is defined as no record of bleeding or spotting indicated in the e-diary and no record of bleeding or spotting Indicated in the alkaline hematin data during the last 56 days of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Month 3 in Uterine Volume</measure>
    <time_frame>Baseline and month 3</time_frame>
    <description>Uterine volume was determined using transabdominal ultrasound. The images were analyzed by a central imaging center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥ 25% Reduction in Uterine Volume at Month 3 / Final Visit</measure>
    <time_frame>Baseline and month 3 or the final visit during the treatment period for participants who prematurely discontinued.</time_frame>
    <description>Uterine volume was determined using transabdominal ultrasound. The images were analyzed by a central imaging center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Month 3 in Volume of the Largest Fibroid</measure>
    <time_frame>Baseline and month 3</time_frame>
    <description>The volume of the largest fibroid was determined using transabdominal ultrasound. The images were analyzed by a central imaging center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥ 25% Reduction in Volume of Largest Fibroid at Month 3 / Final Visit</measure>
    <time_frame>Baseline and month 3 or the final visit during the treatment period for participants who prematurely discontinued.</time_frame>
    <description>The volume of the largest fibroid was determined using transabdominal ultrasound. The images were analyzed by a central imaging center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 3 in the Uterine Fibroid Symptom Quality of Life Questionnaire (UFS-QoL)</measure>
    <time_frame>Baseline and month 3</time_frame>
    <description>The UFS-QoL is a disease-specific, self-administered, validated questionnaire developed to evaluate the symptoms associated with uterine fibroids and their impact on health-related quality of life (HRQL) in women with symptomatic uterine fibroids. The questionnaire consists of 37 questions, divided into 2 parts: 1) an 8-item symptom severity scale and 2) a 29-item HRQL subscale comprising 6 domains (concern, activities, energy/mood, control, self-consiousness, and sexual function), with a 4-week recall. All items are scored on a 5-point scale, ranging from &quot;not at all&quot; to &quot;a very great deal&quot; for symptom severity items and &quot;none of the time&quot; to &quot;all of the time&quot; for the HRQL items. Symptom severity and HRQL subscale scores were summed and transformed into a 0 to 100 point scale to provide a total score for each of the 2 components.
Lower symptom severity scores indicate better quality of life and higher total HRQL scores indicate better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 3 in the Uterine Fibroids Daily Symptom Scale Scores</measure>
    <time_frame>Baseline (average score over the 30 days prior to first dose) and month 3 (average score over days 61 to 90)</time_frame>
    <description>The uterine fibroid daily symptom scale is self-administered questionnaire, with a scale that ranges from 0 to 10 for the symptoms of pelvic pain, fatigue, and cramping and the impact of uterine fibroids on the subject's daily life, with 0 being the absence of the symptom and 10 being the worst severity of the symptoms or completely preventing the subjects from performing daily activities. Participants self-reported values daily in the e-Diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 3 in the Subject Surgery Intention Questionnaire (SSIQ) Version 2.0</measure>
    <time_frame>Baseline and month 3</time_frame>
    <description>The Subject Intention Questionnaire (SSIQ) is a non-validated, exploratory questionnaires intended to evaluate the subject's intent to undergo surgical procedures if current endometriosis-associated symptoms continued. The scoring scale ranged from 0 (not at all likely to consider surgery) to 10 (very likely to consider surgery).
SSIQ included the 2 following questions:
How likely are you to consider having myomectomy surgery to treat your uterine fibroid if your symptoms continue as they are now?
How likely are you to consider hysterectomy surgery if your uterine fibroid symptoms continue as they are now?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 3 in the Physician Surgery Intention Questionnaire (PSIQ) Version 2.0</measure>
    <time_frame>Baseline and month 3</time_frame>
    <description>The Physician Intention Questionnaire (PSIQ) is a non-validated, exploratory questionnaire intended to evaluate the investigator's intent to recommend surgical procedures if current endometriosis-associated symptoms continued. The scoring scale ranged from 0 (not at all likely to recommend surgery) to 10 (very likely to recommend surgery).
The PSIQ included the 2 following questions:
How likely are you to recommend myomectomy to treat this patient's uterine fibroid if her symptoms continue as they are now?
How likely are you to recommend definitive surgery hysterectomy for this patient if her uterine fibroid symptoms continue as they are now?</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">271</enrollment>
  <condition>Heavy Uterine Bleeding</condition>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>Cohort 4 Elagolix 400 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received elagolix 400 mg once a day (QD) for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 Elagolix 100 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received elagolix 100 mg twice a day (BID) for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo to elagolix BID for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Elagolix 200 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received elagolix 200 mg twice a day for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo to elagolix twice a day for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 Elagolix 600 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received elagolix 600 mg once a day for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Elagolix 300 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received elagolix 300 mg twice a day for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received placebo to elagolix BID for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 Elagolix 300 mg BID + CEP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elagolix</intervention_name>
    <description>Elagolix tablets</description>
    <arm_group_label>Cohort 1 Elagolix 200 mg BID</arm_group_label>
    <arm_group_label>Cohort 2 Elagolix 300 mg BID</arm_group_label>
    <arm_group_label>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</arm_group_label>
    <arm_group_label>Cohort 4 Elagolix 100 mg BID</arm_group_label>
    <arm_group_label>Cohort 4 Elagolix 400 mg QD</arm_group_label>
    <arm_group_label>Cohort 5 Elagolix 600 mg QD</arm_group_label>
    <arm_group_label>Cohort 6 Elagolix 300 mg BID + CEP</arm_group_label>
    <other_name>ABT-620</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablets</description>
    <arm_group_label>Cohort 1 Placebo</arm_group_label>
    <arm_group_label>Cohort 2 Placebo</arm_group_label>
    <arm_group_label>Cohort 4 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol/Norethindrone acetate (E2/NETA)</intervention_name>
    <description>A continuous once-daily oral tablet containing estrogen and progestin; the low-dose strength contains estradiol 0.5 mg and norethindrone acetate 0.1 mg.</description>
    <arm_group_label>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</arm_group_label>
    <other_name>Activella®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol</intervention_name>
    <description>1.0 mg micronized estradiol tablets administered once a day</description>
    <arm_group_label>Cohort 6 Elagolix 300 mg BID + CEP</arm_group_label>
    <other_name>Estrace®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Progesterone 200 mg administered during the last 12 days of the 28-day menstrual cycle</description>
    <arm_group_label>Cohort 6 Elagolix 300 mg BID + CEP</arm_group_label>
    <other_name>Prometrium®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is a pre-menopausal female 20 to 49 years of age.

          -  Subject has a diagnosis of uterine fibroids documented by a pelvic ultrasound assessed
             by a central reader and verification that a fibroid present met the following
             criteria:

               -  At least 1 fibroid with diameter ≥ 2 cm (longest diameter), or multiple small
                  fibroids with a total uterine volume of ≥ 200 cm³ to ≤ 2,500 cm³ (approximately
                  22 weeks' gestation) as documented by a centrally read ultrasound.

               -  Only intramural, submucosal non-pedunculated, and subserosal fibroids qualified
                  subjects for enrollment (intracavitary pedunculated fibroids were exclusionary).

               -  Ultrasound procedures were performed during the Screening Period, and subjects
                  were not randomized until the investigator reviewed the central reader results
                  verifying the inclusion requirements.

          -  Subject has a history of regular menstrual cycles between 24 to 35 days.

          -  Subject has heavy uterine bleeding associated with uterine fibroids as evidenced by
             blood loss &gt; 80 mL during 2 screening menstrual cycles, measured by the alkaline
             hematin method.

        Exclusion Criteria:

          -  Subject has had a myomectomy, uterine artery embolization, or high intensity focused
             ultrasound for fibroid destruction within 1 year prior to randomization or any history
             of endometrial ablation.

          -  Subject has a history of osteoporosis or other metabolic bone disease.

          -  Subject shows evidence of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric (including
             depression), or neurologic diseases or any uncontrolled medical illness such as
             uncontrolled type 2 diabetes.

          -  Subject has a history of clinically significant condition(s) including but not limited
             to:

               -  Endometriosis

               -  Epilepsy or seizures

               -  Type 1 diabetes

               -  Any cancer (except basal cell carcinoma of the skin), including breast or ovarian
                  cancer or subject has taken any systemic cancer chemotherapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <removed_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 6, 2011</study_first_submitted>
  <study_first_submitted_qc>September 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2011</study_first_posted>
  <results_first_submitted>June 9, 2020</results_first_submitted>
  <results_first_submitted_qc>July 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 15, 2020</results_first_posted>
  <disposition_first_submitted>November 25, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>November 25, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 11, 2014</disposition_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uterine Fibroids</keyword>
  <keyword>Heavy Uterine Bleeding</keyword>
  <keyword>Elagolix</keyword>
  <keyword>Menorrhagia</keyword>
  <keyword>ABT-620</keyword>
  <keyword>Leiomyomata</keyword>
  <keyword>Elagolix sodium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
    <mesh_term>Uterine Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone Acetate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Overall, 271 female participants were enrolled into the study across 45 sites in the United States.</recruitment_details>
      <pre_assignment_details>Six cohorts of participants were enrolled, with 3 double-blind cohorts comparing elagolix with placebo, 2 open-label cohorts assessing add-back therapies, and 1 open-label cohort assessing the elagolix 600 mg QD dosing regimen.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 4 Elagolix 400 mg QD</title>
          <description>Participants received elagolix 400 mg once a day (QD) for 3 months.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 4 Elagolix 100 mg BID</title>
          <description>Participants received elagolix 100 mg twice a day (BID) for 3 months.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 4 Placebo</title>
          <description>Participants received placebo to elagolix BID for 3 months.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 1 Elagolix 200 mg BID</title>
          <description>Participants received elagolix 200 mg twice a day for 3 months.</description>
        </group>
        <group group_id="P5">
          <title>Cohort 1 Placebo</title>
          <description>Participants received placebo to elagolix twice a day for 3 months.</description>
        </group>
        <group group_id="P6">
          <title>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</title>
          <description>Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.</description>
        </group>
        <group group_id="P7">
          <title>Cohort 5 Elagolix 600 mg QD</title>
          <description>Participants received elagolix 600 mg once a day for 3 months.</description>
        </group>
        <group group_id="P8">
          <title>Cohort 2 Elagolix 300 mg BID</title>
          <description>Participants received elagolix 300 mg twice a day for 3 months.</description>
        </group>
        <group group_id="P9">
          <title>Cohort 2 Placebo</title>
          <description>Participants received placebo to elagolix BID for 3 months.</description>
        </group>
        <group group_id="P10">
          <title>Cohort 6 Elagolix 300 mg BID + CEP</title>
          <description>Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="35"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="34"/>
                <participants group_id="P7" count="30"/>
                <participants group_id="P8" count="30"/>
                <participants group_id="P9" count="16"/>
                <participants group_id="P10" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="29"/>
                <participants group_id="P7" count="24"/>
                <participants group_id="P8" count="26"/>
                <participants group_id="P9" count="14"/>
                <participants group_id="P10" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Surgery or Invasive Intervention</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Received Exclusionary Medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 4 Elagolix 400 mg QD</title>
          <description>Participants received elagolix 400 mg once a day (QD) for 3 months.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 4 Elagolix 100 mg BID</title>
          <description>Participants received elagolix 100 mg twice a day (BID) for 3 months.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 4 Placebo</title>
          <description>Participants received placebo to elagolix BID for 3 months.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 1 Elagolix 200 mg BID</title>
          <description>Participants received elagolix 200 mg twice a day for 3 months.</description>
        </group>
        <group group_id="B5">
          <title>Cohort 1 Placebo</title>
          <description>Participants received placebo to elagolix twice a day for 3 months.</description>
        </group>
        <group group_id="B6">
          <title>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</title>
          <description>Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.</description>
        </group>
        <group group_id="B7">
          <title>Cohort 5 Elagolix 600 mg QD</title>
          <description>Participants received elagolix 600 mg once a day for 3 months.</description>
        </group>
        <group group_id="B8">
          <title>Cohort 2 Elagolix 300 mg BID</title>
          <description>Participants received elagolix 300 mg twice a day for 3 months.</description>
        </group>
        <group group_id="B9">
          <title>Cohort 2 Placebo</title>
          <description>Participants received placebo to elagolix BID for 3 months.</description>
        </group>
        <group group_id="B10">
          <title>Cohort 6 Elagolix 300 mg BID + CEP</title>
          <description>Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="35"/>
            <count group_id="B5" value="18"/>
            <count group_id="B6" value="34"/>
            <count group_id="B7" value="30"/>
            <count group_id="B8" value="30"/>
            <count group_id="B9" value="16"/>
            <count group_id="B10" value="27"/>
            <count group_id="B11" value="271"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.8" spread="5.50"/>
                    <measurement group_id="B2" value="42.1" spread="5.09"/>
                    <measurement group_id="B3" value="41.1" spread="5.88"/>
                    <measurement group_id="B4" value="43.1" spread="4.29"/>
                    <measurement group_id="B5" value="44.0" spread="4.24"/>
                    <measurement group_id="B6" value="40.9" spread="6.02"/>
                    <measurement group_id="B7" value="40.8" spread="5.78"/>
                    <measurement group_id="B8" value="42.6" spread="5.55"/>
                    <measurement group_id="B9" value="41.6" spread="7.10"/>
                    <measurement group_id="B10" value="41.6" spread="5.26"/>
                    <measurement group_id="B11" value="41.8" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt; 35 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>35 to &lt; 40 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>40 to &lt; 45 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="11"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="10"/>
                    <measurement group_id="B11" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 45 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="13"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="34"/>
                    <measurement group_id="B7" value="30"/>
                    <measurement group_id="B8" value="30"/>
                    <measurement group_id="B9" value="16"/>
                    <measurement group_id="B10" value="27"/>
                    <measurement group_id="B11" value="271"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="12"/>
                    <measurement group_id="B11" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="33"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="30"/>
                    <measurement group_id="B9" value="14"/>
                    <measurement group_id="B10" value="15"/>
                    <measurement group_id="B11" value="238"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="11"/>
                    <measurement group_id="B11" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="23"/>
                    <measurement group_id="B9" value="9"/>
                    <measurement group_id="B10" value="15"/>
                    <measurement group_id="B11" value="200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multirace</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline to the Last 28 Days of Treatment in Menstrual Blood Loss (MBL)</title>
        <description>The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.
Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero.</description>
        <time_frame>Baseline (last menstrual cycle during the screening period) and the last 28 days of treatment (approximately days 61 to 90)</time_frame>
        <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants, excluding participants with less than 28 days of treatment. Last observation carried forward (LOCF) imputation was used for participants with no MBL volume reported by alkaline hematin method but with light to heavy bleeding reported in the eDiary.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 4 Elagolix 400 mg QD</title>
            <description>Participants received elagolix 400 mg once a day (QD) for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 4 Elagolix 100 mg BID</title>
            <description>Participants received elagolix 100 mg twice a day (BID) for 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1 Elagolix 200 mg BID</title>
            <description>Participants received elagolix 200 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1 Placebo</title>
            <description>Participants received placebo to elagolix twice a day for 3 months.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</title>
            <description>Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5 Elagolix 600 mg QD</title>
            <description>Participants received elagolix 600 mg once a day for 3 months.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2 Elagolix 300 mg BID</title>
            <description>Participants received elagolix 300 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 6 Elagolix 300 mg BID + CEP</title>
            <description>Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to the Last 28 Days of Treatment in Menstrual Blood Loss (MBL)</title>
          <description>The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.
Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero.</description>
          <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants, excluding participants with less than 28 days of treatment. Last observation carried forward (LOCF) imputation was used for participants with no MBL volume reported by alkaline hematin method but with light to heavy bleeding reported in the eDiary.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="28"/>
                <count group_id="O8" value="30"/>
                <count group_id="O9" value="15"/>
                <count group_id="O10" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213.70" spread="108.08"/>
                    <measurement group_id="O2" value="269.36" spread="163.17"/>
                    <measurement group_id="O3" value="321.73" spread="327.57"/>
                    <measurement group_id="O4" value="335.11" spread="322.68"/>
                    <measurement group_id="O5" value="251.72" spread="160.29"/>
                    <measurement group_id="O6" value="247.70" spread="177.72"/>
                    <measurement group_id="O7" value="215.62" spread="122.84"/>
                    <measurement group_id="O8" value="206.27" spread="125.08"/>
                    <measurement group_id="O9" value="349.17" spread="424.12"/>
                    <measurement group_id="O10" value="257.99" spread="207.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-183.97" spread="132.19"/>
                    <measurement group_id="O2" value="-184.69" spread="187.05"/>
                    <measurement group_id="O3" value="-10.46" spread="85.04"/>
                    <measurement group_id="O4" value="-272.97" spread="271.39"/>
                    <measurement group_id="O5" value="-79.00" spread="161.33"/>
                    <measurement group_id="O6" value="-192.33" spread="191.51"/>
                    <measurement group_id="O7" value="-189.05" spread="151.15"/>
                    <measurement group_id="O8" value="-202.57" spread="127.93"/>
                    <measurement group_id="O9" value="-175.31" spread="342.14"/>
                    <measurement group_id="O10" value="-216.15" spread="157.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as a factor and baseline as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-205.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>45.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-295.77</ci_lower_limit>
            <ci_upper_limit>-116.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as a factor and baseline as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-189.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>44.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-278.33</ci_lower_limit>
            <ci_upper_limit>-101.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as a factor and baseline as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-138.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>40.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-220.18</ci_lower_limit>
            <ci_upper_limit>-55.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as a factor and baseline as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-130.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>37.68</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-206.70</ci_lower_limit>
            <ci_upper_limit>-54.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to the Last 28 Days of Treatment in Menstrual Blood Loss (MBL)</title>
        <description>The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.
Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero.</description>
        <time_frame>Baseline (last menstrual cycle during the screening period) and the last 28 days of treatment (approximately days 61 to 90)</time_frame>
        <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants, excluding participants with less than 28 days of treatment. Last observation carried forward (LOCF) imputation was used for participants with no MBL volume reported by alkaline hematin method but with light to heavy bleeding reported in the electronic diary.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 4 Elagolix 400 mg QD</title>
            <description>Participants received elagolix 400 mg once a day (QD) for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 4 Elagolix 100 mg BID</title>
            <description>Participants received elagolix 100 mg twice a day (BID) for 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1 Elagolix 200 mg BID</title>
            <description>Participants received elagolix 200 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1 Placebo</title>
            <description>Participants received placebo to elagolix twice a day for 3 months.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</title>
            <description>Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5 Elagolix 600 mg QD</title>
            <description>Participants received elagolix 600 mg once a day for 3 months.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2 Elagolix 300 mg BID</title>
            <description>Participants received elagolix 300 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 6 Elagolix 300 mg BID + CEP</title>
            <description>Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to the Last 28 Days of Treatment in Menstrual Blood Loss (MBL)</title>
          <description>The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.
Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero.</description>
          <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants, excluding participants with less than 28 days of treatment. Last observation carried forward (LOCF) imputation was used for participants with no MBL volume reported by alkaline hematin method but with light to heavy bleeding reported in the electronic diary.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="28"/>
                <count group_id="O8" value="30"/>
                <count group_id="O9" value="15"/>
                <count group_id="O10" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-83.83" spread="35.23"/>
                    <measurement group_id="O2" value="-71.85" spread="49.20"/>
                    <measurement group_id="O3" value="-6.98" spread="40.78"/>
                    <measurement group_id="O4" value="-81.03" spread="55.77"/>
                    <measurement group_id="O5" value="-11.12" spread="103.11"/>
                    <measurement group_id="O6" value="-79.60" spread="43.63"/>
                    <measurement group_id="O7" value="-88.58" spread="39.58"/>
                    <measurement group_id="O8" value="-97.31" spread="12.57"/>
                    <measurement group_id="O9" value="-42.64" spread="39.68"/>
                    <measurement group_id="O10" value="-85.39" spread="28.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as a factor and baseline as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-75.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.71</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-102.93</ci_lower_limit>
            <ci_upper_limit>-48.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as a factor and baseline as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-64.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.48</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-91.14</ci_lower_limit>
            <ci_upper_limit>-37.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as a factor and baseline as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-67.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>22.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-113.39</ci_lower_limit>
            <ci_upper_limit>-21.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as a factor and baseline as a covariate.</method_desc>
            <param_type>LS mean Difference</param_type>
            <param_value>-56.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-73.24</ci_lower_limit>
            <ci_upper_limit>-40.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With MBL &lt; 80 mL and With a ≥ 50% Reduction From Baseline in MBL During the Last 28 Days of Treatment</title>
        <description>The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.
Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero.</description>
        <time_frame>Baseline (last menstrual cycle during the screening period) and the last 28 days of treatment (approximately days 61 to 90)</time_frame>
        <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants, excluding participants with less than 28 days of treatment. LOCF imputation was used for participants with no MBL volume reported by alkaline hematin method but with light to heavy bleeding reported in the eDiary.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 4 Elagolix 400 mg QD</title>
            <description>Participants received elagolix 400 mg once a day (QD) for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 4 Elagolix 100 mg BID</title>
            <description>Participants received elagolix 100 mg twice a day (BID) for 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1 Elagolix 200 mg BID</title>
            <description>Participants received elagolix 200 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1 Placebo</title>
            <description>Participants received placebo to elagolix twice a day for 3 months.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</title>
            <description>Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5 Elagolix 600 mg QD</title>
            <description>Participants received elagolix 600 mg once a day for 3 months.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2 Elagolix 300 mg BID</title>
            <description>Participants received elagolix 300 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 6 Elagolix 300 mg BID + CEP</title>
            <description>Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With MBL &lt; 80 mL and With a ≥ 50% Reduction From Baseline in MBL During the Last 28 Days of Treatment</title>
          <description>The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.
Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero.</description>
          <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants, excluding participants with less than 28 days of treatment. LOCF imputation was used for participants with no MBL volume reported by alkaline hematin method but with light to heavy bleeding reported in the eDiary.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="28"/>
                <count group_id="O8" value="30"/>
                <count group_id="O9" value="15"/>
                <count group_id="O10" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="85"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="85"/>
                    <measurement group_id="O7" value="93"/>
                    <measurement group_id="O8" value="97"/>
                    <measurement group_id="O9" value="33"/>
                    <measurement group_id="O10" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With MBL &lt; 80 mL During the Last 28 Days of Treatment</title>
        <description>The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.
Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero.</description>
        <time_frame>The last 28 days of treatment (approximately days 61 to 90)</time_frame>
        <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants, excluding participants with less than 28 days of treatment. LOCF imputation was used for participants with no MBL volume reported by alkaline hematin method but with light to heavy bleeding reported in the eDiary.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 4 Elagolix 400 mg QD</title>
            <description>Participants received elagolix 400 mg once a day (QD) for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 4 Elagolix 100 mg BID</title>
            <description>Participants received elagolix 100 mg twice a day (BID) for 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1 Elagolix 200 mg BID</title>
            <description>Participants received elagolix 200 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1 Placebo</title>
            <description>Participants received placebo to elagolix twice a day for 3 months.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</title>
            <description>Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5 Elagolix 600 mg QD</title>
            <description>Participants received elagolix 600 mg once a day for 3 months.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2 Elagolix 300 mg BID</title>
            <description>Participants received elagolix 300 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 6 Elagolix 300 mg BID + CEP</title>
            <description>Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With MBL &lt; 80 mL During the Last 28 Days of Treatment</title>
          <description>The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.
Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero.</description>
          <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants, excluding participants with less than 28 days of treatment. LOCF imputation was used for participants with no MBL volume reported by alkaline hematin method but with light to heavy bleeding reported in the eDiary.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="28"/>
                <count group_id="O8" value="30"/>
                <count group_id="O9" value="15"/>
                <count group_id="O10" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="85"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="88"/>
                    <measurement group_id="O7" value="93"/>
                    <measurement group_id="O8" value="97"/>
                    <measurement group_id="O9" value="47"/>
                    <measurement group_id="O10" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a ≥ 50% Reduction From Baseline in MBL During the Last 28 Days of Treatment</title>
        <description>The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.
Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero.</description>
        <time_frame>Baseline (last menstrual cycle during the screening period) and the last 28 days of treatment (approximately days 61 to 90)</time_frame>
        <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants, excluding participants with less than 28 days of treatment. LOCF imputation was used for participants with no MBL volume reported by alkaline hematin method but with light to heavy bleeding reported in the eDiary.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 4 Elagolix 400 mg QD</title>
            <description>Participants received elagolix 400 mg once a day (QD) for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 4 Elagolix 100 mg BID</title>
            <description>Participants received elagolix 100 mg twice a day (BID) for 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1 Elagolix 200 mg BID</title>
            <description>Participants received elagolix 200 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1 Placebo</title>
            <description>Participants received placebo to elagolix twice a day for 3 months.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</title>
            <description>Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5 Elagolix 600 mg QD</title>
            <description>Participants received elagolix 600 mg once a day for 3 months.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2 Elagolix 300 mg BID</title>
            <description>Participants received elagolix 300 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 6 Elagolix 300 mg BID + CEP</title>
            <description>Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a ≥ 50% Reduction From Baseline in MBL During the Last 28 Days of Treatment</title>
          <description>The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.
Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero.</description>
          <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants, excluding participants with less than 28 days of treatment. LOCF imputation was used for participants with no MBL volume reported by alkaline hematin method but with light to heavy bleeding reported in the eDiary.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="28"/>
                <count group_id="O8" value="30"/>
                <count group_id="O9" value="15"/>
                <count group_id="O10" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="91"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="85"/>
                    <measurement group_id="O7" value="93"/>
                    <measurement group_id="O8" value="97"/>
                    <measurement group_id="O9" value="40"/>
                    <measurement group_id="O10" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With No Change, Decrease From Baseline, or Increase From Baseline in Hemoglobin at Month 3</title>
        <description>The percentage of subjects with changes in hemoglobin concentration from Baseline to Month 3 in each of the following categories:
No change from baseline in hemoglobin
Decrease from baseline in hemoglobin ≥ -0.5 g/dL
Decrease from baseline in hemoglobin ≥ -1.0 g/dL
Increase from baseline in hemoglobin ≥ 0.5 g/dL
Increase from baseline in hemoglobin ≥ 1.0 g/dL
The above categories are not all mutually exclusive or exhaustive.</description>
        <time_frame>Baseline and Month 3</time_frame>
        <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available hemoglobin data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 4 Elagolix 400 mg QD</title>
            <description>Participants received elagolix 400 mg once a day (QD) for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 4 Elagolix 100 mg BID</title>
            <description>Participants received elagolix 100 mg twice a day (BID) for 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1 Elagolix 200 mg BID</title>
            <description>Participants received elagolix 200 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1 Placebo</title>
            <description>Participants received placebo to elagolix twice a day for 3 months.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</title>
            <description>Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5 Elagolix 600 mg QD</title>
            <description>Participants received elagolix 600 mg once a day for 3 months.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2 Elagolix 300 mg BID</title>
            <description>Participants received elagolix 300 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 6 Elagolix 300 mg BID + CEP</title>
            <description>Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With No Change, Decrease From Baseline, or Increase From Baseline in Hemoglobin at Month 3</title>
          <description>The percentage of subjects with changes in hemoglobin concentration from Baseline to Month 3 in each of the following categories:
No change from baseline in hemoglobin
Decrease from baseline in hemoglobin ≥ -0.5 g/dL
Decrease from baseline in hemoglobin ≥ -1.0 g/dL
Increase from baseline in hemoglobin ≥ 0.5 g/dL
Increase from baseline in hemoglobin ≥ 1.0 g/dL
The above categories are not all mutually exclusive or exhaustive.</description>
          <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available hemoglobin data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="28"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="25"/>
                <count group_id="O9" value="14"/>
                <count group_id="O10" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreases from –0.5 to 0 g/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="14"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="21"/>
                    <measurement group_id="O10" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreases from –1.0 to –0.5 g/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase ≥ 0.5 g/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="67"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="75"/>
                    <measurement group_id="O7" value="83"/>
                    <measurement group_id="O8" value="76"/>
                    <measurement group_id="O9" value="29"/>
                    <measurement group_id="O10" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase ≥ 1.0 g/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="59"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="43"/>
                    <measurement group_id="O7" value="57"/>
                    <measurement group_id="O8" value="52"/>
                    <measurement group_id="O9" value="29"/>
                    <measurement group_id="O10" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin Concentration From Baseline to Month 3</title>
        <time_frame>Baseline and Month 3</time_frame>
        <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available hemoglobin data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 4 Elagolix 400 mg QD</title>
            <description>Participants received elagolix 400 mg once a day (QD) for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 4 Elagolix 100 mg BID</title>
            <description>Participants received elagolix 100 mg twice a day (BID) for 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1 Elagolix 200 mg BID</title>
            <description>Participants received elagolix 200 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1 Placebo</title>
            <description>Participants received placebo to elagolix twice a day for 3 months.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</title>
            <description>Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5 Elagolix 600 mg QD</title>
            <description>Participants received elagolix 600 mg once a day for 3 months.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2 Elagolix 300 mg BID</title>
            <description>Participants received elagolix 300 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 6 Elagolix 300 mg BID + CEP</title>
            <description>Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin Concentration From Baseline to Month 3</title>
          <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available hemoglobin data at baseline and month 3.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="28"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="25"/>
                <count group_id="O9" value="14"/>
                <count group_id="O10" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" spread="0.99"/>
                    <measurement group_id="O2" value="1.30" spread="1.19"/>
                    <measurement group_id="O3" value="-0.43" spread="1.28"/>
                    <measurement group_id="O4" value="1.13" spread="1.29"/>
                    <measurement group_id="O5" value="0.28" spread="1.33"/>
                    <measurement group_id="O6" value="0.92" spread="0.81"/>
                    <measurement group_id="O7" value="1.40" spread="1.18"/>
                    <measurement group_id="O8" value="1.19" spread="0.85"/>
                    <measurement group_id="O9" value="0.31" spread="1.20"/>
                    <measurement group_id="O10" value="1.54" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as a factor and baseline as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>2.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as a factor and baseline as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>2.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.024</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as a factor and baseline as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as a factor and baseline as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 3 in Uterine Bleeding Score</title>
        <description>Participants recorded the previous days' presence and severity of bleeding every morning in an electronic diary (eDiary) according to the Mansfield-Voda-Jorgenson Menstrual Bleeding Scale:
1 (Spotting): A drop or 2 of blood, not even requiring sanitary protection.
2 (Very light): Needing to change the least absorbent tampon or pad 1 to 2 times per day.
3 (Light): Needing to change a low or regular absorbency tampon or pad 2 or 3 times per day.
4 (Moderate): Needing to change a regular absorbency tampon or pad every 3 to 4 hours.
5 (Heavy): Needing to change a high absorbency tampon or pad every 3 to 4 hours.
6 (Very heavy/gushing): Very heavy bleeding, protection hardly works at all; needing to change the highest absorbency tampon or pad every hour or 2.</description>
        <time_frame>Baseline (average bleeding score over the 30 days prior to first dose) and month 3 (average bleeding score over days 61 to 90)</time_frame>
        <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available bleeding score data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 4 Elagolix 400 mg QD</title>
            <description>Participants received elagolix 400 mg once a day (QD) for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 4 Elagolix 100 mg BID</title>
            <description>Participants received elagolix 100 mg twice a day (BID) for 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1 Elagolix 200 mg BID</title>
            <description>Participants received elagolix 200 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1 Placebo</title>
            <description>Participants received placebo to elagolix twice a day for 3 months.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</title>
            <description>Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5 Elagolix 600 mg QD</title>
            <description>Participants received elagolix 600 mg once a day for 3 months.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2 Elagolix 300 mg BID</title>
            <description>Participants received elagolix 300 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 6 Elagolix 300 mg BID + CEP</title>
            <description>Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 3 in Uterine Bleeding Score</title>
          <description>Participants recorded the previous days' presence and severity of bleeding every morning in an electronic diary (eDiary) according to the Mansfield-Voda-Jorgenson Menstrual Bleeding Scale:
1 (Spotting): A drop or 2 of blood, not even requiring sanitary protection.
2 (Very light): Needing to change the least absorbent tampon or pad 1 to 2 times per day.
3 (Light): Needing to change a low or regular absorbency tampon or pad 2 or 3 times per day.
4 (Moderate): Needing to change a regular absorbency tampon or pad every 3 to 4 hours.
5 (Heavy): Needing to change a high absorbency tampon or pad every 3 to 4 hours.
6 (Very heavy/gushing): Very heavy bleeding, protection hardly works at all; needing to change the highest absorbency tampon or pad every hour or 2.</description>
          <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available bleeding score data at baseline and month 3.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="32"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="27"/>
                <count group_id="O9" value="15"/>
                <count group_id="O10" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="0.56"/>
                    <measurement group_id="O2" value="-0.37" spread="0.46"/>
                    <measurement group_id="O3" value="-0.19" spread="0.33"/>
                    <measurement group_id="O4" value="-0.52" spread="0.65"/>
                    <measurement group_id="O5" value="-0.22" spread="0.32"/>
                    <measurement group_id="O6" value="-0.24" spread="0.47"/>
                    <measurement group_id="O7" value="-0.44" spread="0.71"/>
                    <measurement group_id="O8" value="-0.53" spread="0.33"/>
                    <measurement group_id="O9" value="-0.38" spread="0.77"/>
                    <measurement group_id="O10" value="-0.25" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as a factor and baseline as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>-0.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.030</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as a factor and baseline as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.59</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.109</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as a factor and baseline as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.59</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as a factor and baseline as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.80</ci_lower_limit>
            <ci_upper_limit>-0.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 3 in Percentage of Days With Any Uterine Bleeding</title>
        <description>Participants recorded the previous days' presence and severity of bleeding every morning in an electronic diary (eDiary) according to the Mansfield-Voda-Jorgenson Menstrual Bleeding Scale:
1 (Spotting): A drop or 2 of blood, not even requiring sanitary protection.
2 (Very light): Needing to change the least absorbent tampon or pad 1 to 2 times per day.
3 (Light): Needing to change a low or regular absorbency tampon or pad 2 or 3 times per day.
4 (Moderate): Needing to change a regular absorbency tampon or pad every 3 to 4 hours.
5 (Heavy): Needing to change a high absorbency tampon or pad every 3 to 4 hours.
6 (Very heavy/gushing): Very heavy bleeding, protection hardly works at all; needing to change the highest absorbency tampon or pad every hour or 2.
A day with any uterine bleeding is defined as a days with a bleeding score ≥ 1.</description>
        <time_frame>Baseline (average bleeding score over the 30 days prior to first dose) and month 3 (average bleeding score over days 61 to 90)</time_frame>
        <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available bleeding score data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 4 Elagolix 400 mg QD</title>
            <description>Participants received elagolix 400 mg once a day (QD) for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 4 Elagolix 100 mg BID</title>
            <description>Participants received elagolix 100 mg twice a day (BID) for 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1 Elagolix 200 mg BID</title>
            <description>Participants received elagolix 200 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1 Placebo</title>
            <description>Participants received placebo to elagolix twice a day for 3 months.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</title>
            <description>Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5 Elagolix 600 mg QD</title>
            <description>Participants received elagolix 600 mg once a day for 3 months.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2 Elagolix 300 mg BID</title>
            <description>Participants received elagolix 300 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 6 Elagolix 300 mg BID + CEP</title>
            <description>Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 3 in Percentage of Days With Any Uterine Bleeding</title>
          <description>Participants recorded the previous days' presence and severity of bleeding every morning in an electronic diary (eDiary) according to the Mansfield-Voda-Jorgenson Menstrual Bleeding Scale:
1 (Spotting): A drop or 2 of blood, not even requiring sanitary protection.
2 (Very light): Needing to change the least absorbent tampon or pad 1 to 2 times per day.
3 (Light): Needing to change a low or regular absorbency tampon or pad 2 or 3 times per day.
4 (Moderate): Needing to change a regular absorbency tampon or pad every 3 to 4 hours.
5 (Heavy): Needing to change a high absorbency tampon or pad every 3 to 4 hours.
6 (Very heavy/gushing): Very heavy bleeding, protection hardly works at all; needing to change the highest absorbency tampon or pad every hour or 2.
A day with any uterine bleeding is defined as a days with a bleeding score ≥ 1.</description>
          <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available bleeding score data at baseline and month 3.</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="32"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="27"/>
                <count group_id="O9" value="15"/>
                <count group_id="O10" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.22" spread="14.77"/>
                    <measurement group_id="O2" value="-11.00" spread="15.52"/>
                    <measurement group_id="O3" value="-5.78" spread="10.58"/>
                    <measurement group_id="O4" value="-15.82" spread="17.88"/>
                    <measurement group_id="O5" value="-6.99" spread="12.82"/>
                    <measurement group_id="O6" value="3.63" spread="24.74"/>
                    <measurement group_id="O7" value="-15.38" spread="23.21"/>
                    <measurement group_id="O8" value="-16.91" spread="11.13"/>
                    <measurement group_id="O9" value="-13.95" spread="23.83"/>
                    <measurement group_id="O10" value="1.73" spread="26.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as a factor and baseline as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-10.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.90</ci_lower_limit>
            <ci_upper_limit>-1.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.087</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as a factor and baseline as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-7.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.36</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.045</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as a factor and baseline as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-8.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.43</ci_lower_limit>
            <ci_upper_limit>-0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as a factor and baseline as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-13.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.06</ci_lower_limit>
            <ci_upper_limit>-5.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 3 in Percentage of Days With Moderate to Very Heavy Bleeding</title>
        <description>Participants recorded the previous days' presence and severity of bleeding every morning in an electronic diary (eDiary) according to the Mansfield-Voda-Jorgenson Menstrual Bleeding Scale:
1 (Spotting): A drop or 2 of blood, not even requiring sanitary protection.
2 (Very light): Needing to change the least absorbent tampon or pad 1 to 2 times per day.
3 (Light): Needing to change a low or regular absorbency tampon or pad 2 or 3 times per day.
4 (Moderate): Needing to change a regular absorbency tampon or pad every 3 to 4 hours.
5 (Heavy): Needing to change a high absorbency tampon or pad every 3 to 4 hours.
6 (Very heavy/gushing): Very heavy bleeding, protection hardly works at all; needing to change the highest absorbency tampon or pad every hour or 2.
A day with moderate to very heavy bleeding is defined as a days with a bleeding score ≥ 3.</description>
        <time_frame>Baseline (average bleeding score over the 30 days prior to first dose) and month 3 (average bleeding score over days 61 to 90)</time_frame>
        <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available bleeding score data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 4 Elagolix 400 mg QD</title>
            <description>Participants received elagolix 400 mg once a day (QD) for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 4 Elagolix 100 mg BID</title>
            <description>Participants received elagolix 100 mg twice a day (BID) for 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1 Elagolix 200 mg BID</title>
            <description>Participants received elagolix 200 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1 Placebo</title>
            <description>Participants received placebo to elagolix twice a day for 3 months.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</title>
            <description>Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5 Elagolix 600 mg QD</title>
            <description>Participants received elagolix 600 mg once a day for 3 months.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2 Elagolix 300 mg BID</title>
            <description>Participants received elagolix 300 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 6 Elagolix 300 mg BID + CEP</title>
            <description>Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 3 in Percentage of Days With Moderate to Very Heavy Bleeding</title>
          <description>Participants recorded the previous days' presence and severity of bleeding every morning in an electronic diary (eDiary) according to the Mansfield-Voda-Jorgenson Menstrual Bleeding Scale:
1 (Spotting): A drop or 2 of blood, not even requiring sanitary protection.
2 (Very light): Needing to change the least absorbent tampon or pad 1 to 2 times per day.
3 (Light): Needing to change a low or regular absorbency tampon or pad 2 or 3 times per day.
4 (Moderate): Needing to change a regular absorbency tampon or pad every 3 to 4 hours.
5 (Heavy): Needing to change a high absorbency tampon or pad every 3 to 4 hours.
6 (Very heavy/gushing): Very heavy bleeding, protection hardly works at all; needing to change the highest absorbency tampon or pad every hour or 2.
A day with moderate to very heavy bleeding is defined as a days with a bleeding score ≥ 3.</description>
          <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available bleeding score data at baseline and month 3.</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="32"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="27"/>
                <count group_id="O9" value="15"/>
                <count group_id="O10" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.22" spread="9.27"/>
                    <measurement group_id="O2" value="-5.00" spread="7.87"/>
                    <measurement group_id="O3" value="-4.00" spread="5.37"/>
                    <measurement group_id="O4" value="-7.03" spread="10.89"/>
                    <measurement group_id="O5" value="-3.08" spread="5.88"/>
                    <measurement group_id="O6" value="-7.92" spread="6.43"/>
                    <measurement group_id="O7" value="-6.15" spread="8.47"/>
                    <measurement group_id="O8" value="-8.02" spread="5.41"/>
                    <measurement group_id="O9" value="-3.31" spread="10.40"/>
                    <measurement group_id="O10" value="-6.80" spread="10.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as a factor and baseline as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-5.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.56</ci_lower_limit>
            <ci_upper_limit>-1.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-4.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.11</ci_lower_limit>
            <ci_upper_limit>-0.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.194</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as a factor and baseline as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-3.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.75</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.18</ci_lower_limit>
            <ci_upper_limit>1.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as a factor and baseline as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-7.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.33</ci_lower_limit>
            <ci_upper_limit>-3.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Any Uterine Bleeding or Moderate to Very Heavy Uterine Bleeding at Month 3</title>
        <description>Participants recorded the previous days' presence and severity of bleeding every morning in an eDiary according to the Mansfield-Voda-Jorgenson Menstrual Bleeding Scale:
1 (Spotting): A drop or 2 of blood, not even requiring sanitary protection.
2 (Very light): Needing to change the least absorbent tampon or pad 1 to 2 times per day.
3 (Light): Needing to change a low or regular absorbency tampon or pad 2 or 3 times per day.
4 (Moderate): Needing to change a regular absorbency tampon or pad every 3 to 4 hours.
5 (Heavy): Needing to change a high absorbency tampon or pad every 3 to 4 hours.
6 (Very heavy/gushing): Very heavy bleeding, protection hardly works at all; needing to change the highest absorbency tampon or pad every hour or 2.
Any bleeding is defined as a score ≥ 1 and moderate to very heavy bleeding is defined as a score ≥ 3.</description>
        <time_frame>Month 3 (average bleeding score over days 61 to 90)</time_frame>
        <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available bleeding score data at month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 4 Elagolix 400 mg QD</title>
            <description>Participants received elagolix 400 mg once a day (QD) for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 4 Elagolix 100 mg BID</title>
            <description>Participants received elagolix 100 mg twice a day (BID) for 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1 Elagolix 200 mg BID</title>
            <description>Participants received elagolix 200 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1 Placebo</title>
            <description>Participants received placebo to elagolix twice a day for 3 months.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</title>
            <description>Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5 Elagolix 600 mg QD</title>
            <description>Participants received elagolix 600 mg once a day for 3 months.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2 Elagolix 300 mg BID</title>
            <description>Participants received elagolix 300 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 6 Elagolix 300 mg BID + CEP</title>
            <description>Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Uterine Bleeding or Moderate to Very Heavy Uterine Bleeding at Month 3</title>
          <description>Participants recorded the previous days' presence and severity of bleeding every morning in an eDiary according to the Mansfield-Voda-Jorgenson Menstrual Bleeding Scale:
1 (Spotting): A drop or 2 of blood, not even requiring sanitary protection.
2 (Very light): Needing to change the least absorbent tampon or pad 1 to 2 times per day.
3 (Light): Needing to change a low or regular absorbency tampon or pad 2 or 3 times per day.
4 (Moderate): Needing to change a regular absorbency tampon or pad every 3 to 4 hours.
5 (Heavy): Needing to change a high absorbency tampon or pad every 3 to 4 hours.
6 (Very heavy/gushing): Very heavy bleeding, protection hardly works at all; needing to change the highest absorbency tampon or pad every hour or 2.
Any bleeding is defined as a score ≥ 1 and moderate to very heavy bleeding is defined as a score ≥ 3.</description>
          <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available bleeding score data at month 3.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="32"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="27"/>
                <count group_id="O9" value="15"/>
                <count group_id="O10" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="94"/>
                    <measurement group_id="O6" value="78"/>
                    <measurement group_id="O7" value="27"/>
                    <measurement group_id="O8" value="26"/>
                    <measurement group_id="O9" value="80"/>
                    <measurement group_id="O10" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate to Very Heavy Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="87"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="82"/>
                    <measurement group_id="O6" value="31"/>
                    <measurement group_id="O7" value="15"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="73"/>
                    <measurement group_id="O10" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Suppression of Bleeding (Spotting Allowed) or Amenorrhea During the Last 56 Days of Treatment</title>
        <description>Suppression of bleeding is defined as no record of bleeding (spotting allowed) in the e-diary and no record of bleeding Indicated in the alkaline hematin data during the last 56 days of treatment.
Amenorrhea is defined as no record of bleeding or spotting indicated in the e-diary and no record of bleeding or spotting Indicated in the alkaline hematin data during the last 56 days of treatment.</description>
        <time_frame>The last 56 days of treatment (approximately days 33 to 90)</time_frame>
        <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants including participants with less than 56 days of treatment who bled but excluded those who did not bleed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 4 Elagolix 400 mg QD</title>
            <description>Participants received elagolix 400 mg once a day (QD) for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 4 Elagolix 100 mg BID</title>
            <description>Participants received elagolix 100 mg twice a day (BID) for 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1 Elagolix 200 mg BID</title>
            <description>Participants received elagolix 200 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1 Placebo</title>
            <description>Participants received placebo to elagolix twice a day for 3 months.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</title>
            <description>Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5 Elagolix 600 mg QD</title>
            <description>Participants received elagolix 600 mg once a day for 3 months.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2 Elagolix 300 mg BID</title>
            <description>Participants received elagolix 300 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 6 Elagolix 300 mg BID + CEP</title>
            <description>Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Suppression of Bleeding (Spotting Allowed) or Amenorrhea During the Last 56 Days of Treatment</title>
          <description>Suppression of bleeding is defined as no record of bleeding (spotting allowed) in the e-diary and no record of bleeding Indicated in the alkaline hematin data during the last 56 days of treatment.
Amenorrhea is defined as no record of bleeding or spotting indicated in the e-diary and no record of bleeding or spotting Indicated in the alkaline hematin data during the last 56 days of treatment.</description>
          <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants including participants with less than 56 days of treatment who bled but excluded those who did not bleed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="32"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="29"/>
                <count group_id="O9" value="16"/>
                <count group_id="O10" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Suppression of bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="66"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="31"/>
                    <measurement group_id="O7" value="77"/>
                    <measurement group_id="O8" value="79"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amenorrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="44"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="19"/>
                    <measurement group_id="O7" value="73"/>
                    <measurement group_id="O8" value="66"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Month 3 in Uterine Volume</title>
        <description>Uterine volume was determined using transabdominal ultrasound. The images were analyzed by a central imaging center.</description>
        <time_frame>Baseline and month 3</time_frame>
        <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available uterine volume data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 4 Elagolix 400 mg QD</title>
            <description>Participants received elagolix 400 mg once a day (QD) for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 4 Elagolix 100 mg BID</title>
            <description>Participants received elagolix 100 mg twice a day (BID) for 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1 Elagolix 200 mg BID</title>
            <description>Participants received elagolix 200 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1 Placebo</title>
            <description>Participants received placebo to elagolix twice a day for 3 months.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</title>
            <description>Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5 Elagolix 600 mg QD</title>
            <description>Participants received elagolix 600 mg once a day for 3 months.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2 Elagolix 300 mg BID</title>
            <description>Participants received elagolix 300 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 6 Elagolix 300 mg BID + CEP</title>
            <description>Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Month 3 in Uterine Volume</title>
          <description>Uterine volume was determined using transabdominal ultrasound. The images were analyzed by a central imaging center.</description>
          <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available uterine volume data at baseline and month 3.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="22"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.01" spread="26.79"/>
                    <measurement group_id="O2" value="-21.37" spread="24.84"/>
                    <measurement group_id="O3" value="18.72" spread="15.59"/>
                    <measurement group_id="O4" value="-21.68" spread="29.80"/>
                    <measurement group_id="O5" value="-8.62" spread="20.58"/>
                    <measurement group_id="O6" value="-17.43" spread="19.51"/>
                    <measurement group_id="O7" value="-27.99" spread="23.34"/>
                    <measurement group_id="O8" value="-33.25" spread="16.55"/>
                    <measurement group_id="O9" value="-1.92" spread="17.52"/>
                    <measurement group_id="O10" value="-10.06" spread="30.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Kruskal-Wallis</method>
            <method_desc>One-way Kruskal-Wallis test with treatment as a factor.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Kruskal-Wallis</method>
            <method_desc>One-way Kruskal-Wallis test with treatment as a factor.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.052</p_value>
            <method>Kruskal-Wallis</method>
            <method_desc>One-way Kruskal-Wallis test with treatment as a factor.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Kruskal-Wallis</method>
            <method_desc>One-way Kruskal-Wallis test with treatment as a factor.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ≥ 25% Reduction in Uterine Volume at Month 3 / Final Visit</title>
        <description>Uterine volume was determined using transabdominal ultrasound. The images were analyzed by a central imaging center.</description>
        <time_frame>Baseline and month 3 or the final visit during the treatment period for participants who prematurely discontinued.</time_frame>
        <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available uterine volume data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 4 Elagolix 400 mg QD</title>
            <description>Participants received elagolix 400 mg once a day (QD) for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 4 Elagolix 100 mg BID</title>
            <description>Participants received elagolix 100 mg twice a day (BID) for 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1 Elagolix 200 mg BID</title>
            <description>Participants received elagolix 200 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1 Placebo</title>
            <description>Participants received placebo to elagolix twice a day for 3 months.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</title>
            <description>Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5 Elagolix 600 mg QD</title>
            <description>Participants received elagolix 600 mg once a day for 3 months.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2 Elagolix 300 mg BID</title>
            <description>Participants received elagolix 300 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 6 Elagolix 300 mg BID + CEP</title>
            <description>Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥ 25% Reduction in Uterine Volume at Month 3 / Final Visit</title>
          <description>Uterine volume was determined using transabdominal ultrasound. The images were analyzed by a central imaging center.</description>
          <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available uterine volume data at baseline and month 3.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="27"/>
                <count group_id="O8" value="29"/>
                <count group_id="O9" value="15"/>
                <count group_id="O10" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="48"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="42"/>
                    <measurement group_id="O7" value="56"/>
                    <measurement group_id="O8" value="69"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Month 3 in Volume of the Largest Fibroid</title>
        <description>The volume of the largest fibroid was determined using transabdominal ultrasound. The images were analyzed by a central imaging center.</description>
        <time_frame>Baseline and month 3</time_frame>
        <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available fibroid volume data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 4 Elagolix 400 mg QD</title>
            <description>Participants received elagolix 400 mg once a day (QD) for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 4 Elagolix 100 mg BID</title>
            <description>Participants received elagolix 100 mg twice a day (BID) for 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1 Elagolix 200 mg BID</title>
            <description>Participants received elagolix 200 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1 Placebo</title>
            <description>Participants received placebo to elagolix twice a day for 3 months.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</title>
            <description>Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5 Elagolix 600 mg QD</title>
            <description>Participants received elagolix 600 mg once a day for 3 months.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2 Elagolix 300 mg BID</title>
            <description>Participants received elagolix 300 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 6 Elagolix 300 mg BID + CEP</title>
            <description>Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Month 3 in Volume of the Largest Fibroid</title>
          <description>The volume of the largest fibroid was determined using transabdominal ultrasound. The images were analyzed by a central imaging center.</description>
          <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available fibroid volume data at baseline and month 3.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="22"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.23" spread="187.83"/>
                    <measurement group_id="O2" value="-22.19" spread="51.14"/>
                    <measurement group_id="O3" value="-7.26" spread="36.35"/>
                    <measurement group_id="O4" value="-38.52" spread="41.72"/>
                    <measurement group_id="O5" value="-2.05" spread="71.83"/>
                    <measurement group_id="O6" value="-25.77" spread="46.64"/>
                    <measurement group_id="O7" value="-16.60" spread="39.61"/>
                    <measurement group_id="O8" value="-35.79" spread="24.49"/>
                    <measurement group_id="O9" value="6.70" spread="45.42"/>
                    <measurement group_id="O10" value="-4.94" spread="100.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.161</p_value>
            <method>Kruskal-Wallis</method>
            <method_desc>One-way Kruskal-Wallis test with treatment as a factor</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.173</p_value>
            <method>Kruskal-Wallis</method>
            <method_desc>One-way Kruskal-Wallis test with treatment as a factor.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.072</p_value>
            <method>Kruskal-Wallis</method>
            <method_desc>One-way Kruskal-Wallis test with treatment as a factor.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Kruskal-Wallis</method>
            <method_desc>One-way Kruskal-Wallis test with treatment as a factor.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ≥ 25% Reduction in Volume of Largest Fibroid at Month 3 / Final Visit</title>
        <description>The volume of the largest fibroid was determined using transabdominal ultrasound. The images were analyzed by a central imaging center.</description>
        <time_frame>Baseline and month 3 or the final visit during the treatment period for participants who prematurely discontinued.</time_frame>
        <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available uterine volume data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 4 Elagolix 400 mg QD</title>
            <description>Participants received elagolix 400 mg once a day (QD) for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 4 Elagolix 100 mg BID</title>
            <description>Participants received elagolix 100 mg twice a day (BID) for 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1 Elagolix 200 mg BID</title>
            <description>Participants received elagolix 200 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1 Placebo</title>
            <description>Participants received placebo to elagolix twice a day for 3 months.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</title>
            <description>Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5 Elagolix 600 mg QD</title>
            <description>Participants received elagolix 600 mg once a day for 3 months.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2 Elagolix 300 mg BID</title>
            <description>Participants received elagolix 300 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 6 Elagolix 300 mg BID + CEP</title>
            <description>Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥ 25% Reduction in Volume of Largest Fibroid at Month 3 / Final Visit</title>
          <description>The volume of the largest fibroid was determined using transabdominal ultrasound. The images were analyzed by a central imaging center.</description>
          <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available uterine volume data at baseline and month 3.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="29"/>
                <count group_id="O9" value="15"/>
                <count group_id="O10" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="68"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="58"/>
                    <measurement group_id="O7" value="60"/>
                    <measurement group_id="O8" value="55"/>
                    <measurement group_id="O9" value="27"/>
                    <measurement group_id="O10" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.203</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.342</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.111</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 3 in the Uterine Fibroid Symptom Quality of Life Questionnaire (UFS-QoL)</title>
        <description>The UFS-QoL is a disease-specific, self-administered, validated questionnaire developed to evaluate the symptoms associated with uterine fibroids and their impact on health-related quality of life (HRQL) in women with symptomatic uterine fibroids. The questionnaire consists of 37 questions, divided into 2 parts: 1) an 8-item symptom severity scale and 2) a 29-item HRQL subscale comprising 6 domains (concern, activities, energy/mood, control, self-consiousness, and sexual function), with a 4-week recall. All items are scored on a 5-point scale, ranging from &quot;not at all&quot; to &quot;a very great deal&quot; for symptom severity items and &quot;none of the time&quot; to &quot;all of the time&quot; for the HRQL items. Symptom severity and HRQL subscale scores were summed and transformed into a 0 to 100 point scale to provide a total score for each of the 2 components.
Lower symptom severity scores indicate better quality of life and higher total HRQL scores indicate better quality of life.</description>
        <time_frame>Baseline and month 3</time_frame>
        <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available UFS-QoL data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 4 Elagolix 400 mg QD</title>
            <description>Participants received elagolix 400 mg once a day (QD) for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 4 Elagolix 100 mg BID</title>
            <description>Participants received elagolix 100 mg twice a day (BID) for 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1 Elagolix 200 mg BID</title>
            <description>Participants received elagolix 200 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1 Placebo</title>
            <description>Participants received placebo to elagolix twice a day for 3 months.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</title>
            <description>Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5 Elagolix 600 mg QD</title>
            <description>Participants received elagolix 600 mg once a day for 3 months.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2 Elagolix 300 mg BID</title>
            <description>Participants received elagolix 300 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 6 Elagolix 300 mg BID + CEP</title>
            <description>Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 3 in the Uterine Fibroid Symptom Quality of Life Questionnaire (UFS-QoL)</title>
          <description>The UFS-QoL is a disease-specific, self-administered, validated questionnaire developed to evaluate the symptoms associated with uterine fibroids and their impact on health-related quality of life (HRQL) in women with symptomatic uterine fibroids. The questionnaire consists of 37 questions, divided into 2 parts: 1) an 8-item symptom severity scale and 2) a 29-item HRQL subscale comprising 6 domains (concern, activities, energy/mood, control, self-consiousness, and sexual function), with a 4-week recall. All items are scored on a 5-point scale, ranging from &quot;not at all&quot; to &quot;a very great deal&quot; for symptom severity items and &quot;none of the time&quot; to &quot;all of the time&quot; for the HRQL items. Symptom severity and HRQL subscale scores were summed and transformed into a 0 to 100 point scale to provide a total score for each of the 2 components.
Lower symptom severity scores indicate better quality of life and higher total HRQL scores indicate better quality of life.</description>
          <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available UFS-QoL data at baseline and month 3.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="22"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="25"/>
                <count group_id="O9" value="13"/>
                <count group_id="O10" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Symptom severity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="22"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="25"/>
                    <count group_id="O9" value="13"/>
                    <count group_id="O10" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.0" spread="24.70"/>
                    <measurement group_id="O2" value="-33.2" spread="28.17"/>
                    <measurement group_id="O3" value="-19.6" spread="32.80"/>
                    <measurement group_id="O4" value="-31.6" spread="28.87"/>
                    <measurement group_id="O5" value="-21.4" spread="20.63"/>
                    <measurement group_id="O6" value="-20.3" spread="25.35"/>
                    <measurement group_id="O7" value="-36.4" spread="24.74"/>
                    <measurement group_id="O8" value="-44.1" spread="22.12"/>
                    <measurement group_id="O9" value="-12.0" spread="22.49"/>
                    <measurement group_id="O10" value="-39.1" spread="24.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HRQL total</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="22"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="25"/>
                    <count group_id="O9" value="13"/>
                    <count group_id="O10" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3" spread="21.87"/>
                    <measurement group_id="O2" value="29.1" spread="30.96"/>
                    <measurement group_id="O3" value="16.3" spread="30.43"/>
                    <measurement group_id="O4" value="36.0" spread="27.91"/>
                    <measurement group_id="O5" value="18.3" spread="36.66"/>
                    <measurement group_id="O6" value="28.6" spread="24.12"/>
                    <measurement group_id="O7" value="29.9" spread="30.72"/>
                    <measurement group_id="O8" value="33.5" spread="29.42"/>
                    <measurement group_id="O9" value="11.0" spread="20.90"/>
                    <measurement group_id="O10" value="33.1" spread="30.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 3 in the Uterine Fibroids Daily Symptom Scale Scores</title>
        <description>The uterine fibroid daily symptom scale is self-administered questionnaire, with a scale that ranges from 0 to 10 for the symptoms of pelvic pain, fatigue, and cramping and the impact of uterine fibroids on the subject's daily life, with 0 being the absence of the symptom and 10 being the worst severity of the symptoms or completely preventing the subjects from performing daily activities. Participants self-reported values daily in the e-Diary.</description>
        <time_frame>Baseline (average score over the 30 days prior to first dose) and month 3 (average score over days 61 to 90)</time_frame>
        <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 4 Elagolix 400 mg QD</title>
            <description>Participants received elagolix 400 mg once a day (QD) for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 4 Elagolix 100 mg BID</title>
            <description>Participants received elagolix 100 mg twice a day (BID) for 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1 Elagolix 200 mg BID</title>
            <description>Participants received elagolix 200 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1 Placebo</title>
            <description>Participants received placebo to elagolix twice a day for 3 months.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</title>
            <description>Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5 Elagolix 600 mg QD</title>
            <description>Participants received elagolix 600 mg once a day for 3 months.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2 Elagolix 300 mg BID</title>
            <description>Participants received elagolix 300 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 6 Elagolix 300 mg BID + CEP</title>
            <description>Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 3 in the Uterine Fibroids Daily Symptom Scale Scores</title>
          <description>The uterine fibroid daily symptom scale is self-administered questionnaire, with a scale that ranges from 0 to 10 for the symptoms of pelvic pain, fatigue, and cramping and the impact of uterine fibroids on the subject's daily life, with 0 being the absence of the symptom and 10 being the worst severity of the symptoms or completely preventing the subjects from performing daily activities. Participants self-reported values daily in the e-Diary.</description>
          <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available data at baseline and month 3.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="22"/>
                <count group_id="O7" value="16"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pelvic pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="2.27"/>
                    <measurement group_id="O2" value="-0.2" spread="2.39"/>
                    <measurement group_id="O3" value="-0.3" spread="1.45"/>
                    <measurement group_id="O4" value="-0.6" spread="1.75"/>
                    <measurement group_id="O5" value="-1.4" spread="1.62"/>
                    <measurement group_id="O6" value="-1.1" spread="1.35"/>
                    <measurement group_id="O7" value="-0.9" spread="2.15"/>
                    <measurement group_id="O8" value="-1.0" spread="1.75"/>
                    <measurement group_id="O9" value="-1.2" spread="1.73"/>
                    <measurement group_id="O10" value="-2.4" spread="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.26"/>
                    <measurement group_id="O2" value="-0.0" spread="2.23"/>
                    <measurement group_id="O3" value="-0.6" spread="1.45"/>
                    <measurement group_id="O4" value="-0.6" spread="1.29"/>
                    <measurement group_id="O5" value="-0.5" spread="1.69"/>
                    <measurement group_id="O6" value="-1.2" spread="1.92"/>
                    <measurement group_id="O7" value="-1.0" spread="2.57"/>
                    <measurement group_id="O8" value="-1.5" spread="1.16"/>
                    <measurement group_id="O9" value="-0.5" spread="2.88"/>
                    <measurement group_id="O10" value="-2.1" spread="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Menstrual cramping</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="1.31"/>
                    <measurement group_id="O2" value="-0.7" spread="2.51"/>
                    <measurement group_id="O3" value="-0.5" spread="1.55"/>
                    <measurement group_id="O4" value="-0.9" spread="1.16"/>
                    <measurement group_id="O5" value="-1.2" spread="0.80"/>
                    <measurement group_id="O6" value="-0.9" spread="1.25"/>
                    <measurement group_id="O7" value="-1.1" spread="1.35"/>
                    <measurement group_id="O8" value="-1.2" spread="1.09"/>
                    <measurement group_id="O9" value="-1.0" spread="2.33"/>
                    <measurement group_id="O10" value="-1.3" spread="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impact of uterine fibroids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="1.18"/>
                    <measurement group_id="O2" value="-0.4" spread="1.86"/>
                    <measurement group_id="O3" value="-0.8" spread="1.40"/>
                    <measurement group_id="O4" value="-1.0" spread="1.37"/>
                    <measurement group_id="O5" value="-1.0" spread="1.81"/>
                    <measurement group_id="O6" value="-0.9" spread="1.62"/>
                    <measurement group_id="O7" value="-1.7" spread="2.41"/>
                    <measurement group_id="O8" value="-1.3" spread="1.11"/>
                    <measurement group_id="O9" value="-1.0" spread="2.18"/>
                    <measurement group_id="O10" value="-3.1" spread="2.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 3 in the Subject Surgery Intention Questionnaire (SSIQ) Version 2.0</title>
        <description>The Subject Intention Questionnaire (SSIQ) is a non-validated, exploratory questionnaires intended to evaluate the subject's intent to undergo surgical procedures if current endometriosis-associated symptoms continued. The scoring scale ranged from 0 (not at all likely to consider surgery) to 10 (very likely to consider surgery).
SSIQ included the 2 following questions:
How likely are you to consider having myomectomy surgery to treat your uterine fibroid if your symptoms continue as they are now?
How likely are you to consider hysterectomy surgery if your uterine fibroid symptoms continue as they are now?</description>
        <time_frame>Baseline and month 3</time_frame>
        <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 4 Elagolix 400 mg QD</title>
            <description>Participants received elagolix 400 mg once a day (QD) for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 4 Elagolix 100 mg BID</title>
            <description>Participants received elagolix 100 mg twice a day (BID) for 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1 Elagolix 200 mg BID</title>
            <description>Participants received elagolix 200 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1 Placebo</title>
            <description>Participants received placebo to elagolix twice a day for 3 months.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</title>
            <description>Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5 Elagolix 600 mg QD</title>
            <description>Participants received elagolix 600 mg once a day for 3 months.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2 Elagolix 300 mg BID</title>
            <description>Participants received elagolix 300 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 6 Elagolix 300 mg BID + CEP</title>
            <description>Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 3 in the Subject Surgery Intention Questionnaire (SSIQ) Version 2.0</title>
          <description>The Subject Intention Questionnaire (SSIQ) is a non-validated, exploratory questionnaires intended to evaluate the subject's intent to undergo surgical procedures if current endometriosis-associated symptoms continued. The scoring scale ranged from 0 (not at all likely to consider surgery) to 10 (very likely to consider surgery).
SSIQ included the 2 following questions:
How likely are you to consider having myomectomy surgery to treat your uterine fibroid if your symptoms continue as they are now?
How likely are you to consider hysterectomy surgery if your uterine fibroid symptoms continue as they are now?</description>
          <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available data at baseline and month 3.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="22"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="25"/>
                <count group_id="O9" value="13"/>
                <count group_id="O10" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Likelihood of having myomectomy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="22"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="25"/>
                    <count group_id="O9" value="13"/>
                    <count group_id="O10" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="3.68"/>
                    <measurement group_id="O2" value="-3.1" spread="4.52"/>
                    <measurement group_id="O3" value="1.0" spread="2.12"/>
                    <measurement group_id="O4" value="-1.8" spread="4.70"/>
                    <measurement group_id="O5" value="2.3" spread="5.35"/>
                    <measurement group_id="O6" value="-1.4" spread="4.34"/>
                    <measurement group_id="O7" value="-1.7" spread="4.18"/>
                    <measurement group_id="O8" value="-0.6" spread="5.10"/>
                    <measurement group_id="O9" value="0.4" spread="4.16"/>
                    <measurement group_id="O10" value="0.1" spread="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Likelihood of having hysterectomy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="22"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="25"/>
                    <count group_id="O9" value="13"/>
                    <count group_id="O10" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="4.04"/>
                    <measurement group_id="O2" value="-1.9" spread="4.19"/>
                    <measurement group_id="O3" value="2.0" spread="3.64"/>
                    <measurement group_id="O4" value="-0.8" spread="4.91"/>
                    <measurement group_id="O5" value="-0.3" spread="0.52"/>
                    <measurement group_id="O6" value="-0.7" spread="3.10"/>
                    <measurement group_id="O7" value="-0.8" spread="4.42"/>
                    <measurement group_id="O8" value="0.2" spread="3.65"/>
                    <measurement group_id="O9" value="0.0" spread="1.96"/>
                    <measurement group_id="O10" value="-1.5" spread="3.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 3 in the Physician Surgery Intention Questionnaire (PSIQ) Version 2.0</title>
        <description>The Physician Intention Questionnaire (PSIQ) is a non-validated, exploratory questionnaire intended to evaluate the investigator's intent to recommend surgical procedures if current endometriosis-associated symptoms continued. The scoring scale ranged from 0 (not at all likely to recommend surgery) to 10 (very likely to recommend surgery).
The PSIQ included the 2 following questions:
How likely are you to recommend myomectomy to treat this patient's uterine fibroid if her symptoms continue as they are now?
How likely are you to recommend definitive surgery hysterectomy for this patient if her uterine fibroid symptoms continue as they are now?</description>
        <time_frame>Baseline and month 3</time_frame>
        <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available data at baseline and month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 4 Elagolix 400 mg QD</title>
            <description>Participants received elagolix 400 mg once a day (QD) for 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 4 Elagolix 100 mg BID</title>
            <description>Participants received elagolix 100 mg twice a day (BID) for 3 months.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1 Elagolix 200 mg BID</title>
            <description>Participants received elagolix 200 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1 Placebo</title>
            <description>Participants received placebo to elagolix twice a day for 3 months.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</title>
            <description>Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5 Elagolix 600 mg QD</title>
            <description>Participants received elagolix 600 mg once a day for 3 months.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2 Elagolix 300 mg BID</title>
            <description>Participants received elagolix 300 mg twice a day for 3 months.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2 Placebo</title>
            <description>Participants received placebo to elagolix BID for 3 months.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 6 Elagolix 300 mg BID + CEP</title>
            <description>Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 3 in the Physician Surgery Intention Questionnaire (PSIQ) Version 2.0</title>
          <description>The Physician Intention Questionnaire (PSIQ) is a non-validated, exploratory questionnaire intended to evaluate the investigator's intent to recommend surgical procedures if current endometriosis-associated symptoms continued. The scoring scale ranged from 0 (not at all likely to recommend surgery) to 10 (very likely to recommend surgery).
The PSIQ included the 2 following questions:
How likely are you to recommend myomectomy to treat this patient's uterine fibroid if her symptoms continue as they are now?
How likely are you to recommend definitive surgery hysterectomy for this patient if her uterine fibroid symptoms continue as they are now?</description>
          <population>Randomized (Cohorts 1, 2, and 4) or treated (Cohorts 3, 5, and 6) participants with available data at baseline and month 3.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="22"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="24"/>
                <count group_id="O9" value="13"/>
                <count group_id="O10" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Likelihood to recommend myomectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="2.86"/>
                    <measurement group_id="O2" value="-1.3" spread="3.31"/>
                    <measurement group_id="O3" value="-2.7" spread="3.53"/>
                    <measurement group_id="O4" value="-0.8" spread="1.76"/>
                    <measurement group_id="O5" value="0.7" spread="1.11"/>
                    <measurement group_id="O6" value="-0.6" spread="2.97"/>
                    <measurement group_id="O7" value="-1.3" spread="3.62"/>
                    <measurement group_id="O8" value="-1.2" spread="3.59"/>
                    <measurement group_id="O9" value="0.0" spread="3.25"/>
                    <measurement group_id="O10" value="0.0" spread="3.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Likelihood to recommend hysterectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="3.34"/>
                    <measurement group_id="O2" value="-1.8" spread="4.37"/>
                    <measurement group_id="O3" value="-0.2" spread="3.15"/>
                    <measurement group_id="O4" value="-2.2" spread="2.82"/>
                    <measurement group_id="O5" value="0.4" spread="1.62"/>
                    <measurement group_id="O6" value="-1.4" spread="3.08"/>
                    <measurement group_id="O7" value="-2.3" spread="3.99"/>
                    <measurement group_id="O8" value="-1.5" spread="3.96"/>
                    <measurement group_id="O9" value="-0.6" spread="2.81"/>
                    <measurement group_id="O10" value="-2.8" spread="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the date of the first dose of study drug through up to 30 days after the last dose of study drug, up to 4 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1 Placebo</title>
          <description>Participants received placebo to elagolix twice a day for 3 months.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1 Elagolix 200 mg BID</title>
          <description>Participants received elagolix 200 mg twice a day for 3 months.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 2 Placebo</title>
          <description>Participants received placebo to elagolix BID for 3 months.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 2 Elagolix 300 mg BID</title>
          <description>Participants received elagolix 300 mg twice a day for 3 months</description>
        </group>
        <group group_id="E5">
          <title>Cohort 3 Elagolix 200 mg BID + LD E2/NETA</title>
          <description>Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.</description>
        </group>
        <group group_id="E6">
          <title>Cohort 4 Placebo</title>
          <description>Participants received placebo to elagolix BID for 3 months.</description>
        </group>
        <group group_id="E7">
          <title>Cohort 4 Elagolix 100 mg BID</title>
          <description>Participants received elagolix 100 mg twice a day (BID) for 3 months.</description>
        </group>
        <group group_id="E8">
          <title>Cohort 4 Golix 400 mg QD</title>
          <description>Participants received elagolix 400 mg once a day (QD) for 3 months.</description>
        </group>
        <group group_id="E9">
          <title>Cohort 5 Elagolix 600 mg QD</title>
          <description>Participants received elagolix 600 mg once a day for 3 months.</description>
        </group>
        <group group_id="E10">
          <title>Cohort 6 Elagolix 300 mg BID + CEP</title>
          <description>Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>UTERINE LEIOMYOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>UTERINE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>ABORTION INDUCED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="24" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="22" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E10" events="5" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E9" events="9" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>PEPTIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>VESSEL PUNCTURE SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>VAGINITIS BACTERIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>FUNGAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>VULVOVAGINITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>FURUNCLE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>INFECTED BITES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD PRESSURE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>OSTEOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E9" events="6" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E9" events="11" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>BALANCE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>MOOD SWINGS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>LIBIDO DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>POLLAKIURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>DYSMENORRHOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>MENORRHAGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>PELVIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>VULVOVAGINAL DRYNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>AMENORRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>BREAST CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>METRORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>DYSPAREUNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>OVARIAN CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ACNE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>NIGHT SWEATS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>RASH GENERALISED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>RASH MACULAR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>CHLOASMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HOT FLUSH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="35"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" events="15" subjects_affected="15" subjects_at_risk="30"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="34"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E7" events="16" subjects_affected="15" subjects_at_risk="33"/>
                <counts group_id="E8" events="21" subjects_affected="20" subjects_at_risk="32"/>
                <counts group_id="E9" events="15" subjects_affected="15" subjects_at_risk="30"/>
                <counts group_id="E10" events="5" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>SPIDER VEIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie (prior sponsor, Abbott)</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

